Kampala, (UG): The Uganda Aids Commission (UAC)has revealed that Uganda will in a period of less than three months join three other African countries in the rolling out of the injectable drug approved for HIV/Aids prevention.
The long-lasting injectable cabotegravir (CAB-LA) has been confirmed to be effective by the World Health Organization (WHO) and is already being considered as a key element to national efforts to reduce the health burden of HIV/Aids, which claimed 17,000 lives in Uganda last year.
The development was revealed by Dr Daniel Byamukama, head of the HIV prevention division at the Commission in a press conference on Monday where he told the media that the planned rollout of the drug will begin early next year, before hailing it as an effective, safe and more user-friendly disease prevention measure compared to existing options.
“We have made orders using the Global Fund for [HIV/Aids, Malaria and Tuberculosis] for injectable pre-exposure prophylaxis (PrEP). You take one injection every two months. If you are HIV negative you will not contract HIV,” Dr Byamukama said.
He added that the commission is targeting 10,000 people in the first year, and will be increased by 10,000 in the subsequent years to be benefiting from this.
“But if the need is so high, I promise that we shall make it available,” Dr Byamukama said without indicating which criteria is to be used to pick the very first beneficiaries in the programme.
Dr Byamumaka explained that what remains is for relevant health regulatory agencies to give final endorsement for local applications in Uganda.
“We are sure all the national approvals will be ready by the end of this year and that injectable PrEP will be available for countrymen and women, starting January next year. It will be completely free of charge,” he added.
The injectable cabotegravir drug was cleared by the World Health Organisation (WHO) after studies showed it is safe and effective in preventing HIV infection and more convenient than oral pills, Dr Byamukama revealed.
The drug is produced under patent by ViiV Healthcare, a partnership of pharmaceutical corporations Pfizer, GlaxoSmithKline and Shionogi based in the United Kingdom.
According to a 2020 report by the WHO, one of the trials for the drug was done among 3,223 women aged 18-45 years in 20 sites in Uganda, Botswana, Kenya, Malawi, South Africa, Eswatini and Zimbabwe.
“Thirty-eight women in the trial acquired HIV. Four were randomised to the long-acting cabotegravir arm (long-acting injectable PrEP for HIV) and 34 were randomised to the daily, oral Tenofovir/emtricitabine (FTC/TDF) arm,” the WHO report indicates.
National statistics from the Uganda Aids Commission indicate that HIV/AIDs is very prevalent among women aged 15 to 49 years (6.5 per cent), compared to 3.6 per cent for men in the same age bracket.
Being an injectable, the revolutionary drug has been welcomed by UAC officials as an appropriate option for especially women given the cultural sensitivities around sexual matters in socially conservative settings like Uganda.
“Injectable PrEP has one advantage; that it is discreet. Most of the affected people are women. A woman carrying a box of oral PrEP pills is prone to violence from her partner. She is prone to being accused of promiscuity,” Dr Byamukama said.
“For an injectable, you walk into the pharmacy or the hospital, you get one injection once in two months. That is quite discreet. Your husband or partner will never know about it so the controlling behaviour of sexual partners that always stop women from accessing these services will be addressed,” he added.
“We are sure that after getting all necessary national approvals by the end of this year, and by January next year, people will have begun accessing for prevention. We are targeting all sexually active people who consider themselves at high risk. If you are married to a sex worker or your husband has multiple sexual partners; you are married to a person who is HIV positive, and/or you are a sex worker…, it is safe and effective,” he said.
Other countries rolling out the drug
In November last year, WHO announced that the Medicines Control Authority of Zimbabwe had approved the use of long-acting injectable cabotegravir as pre-exposure prophylaxis for HIV.
A few months later in March this year, ViiV Healthcare issued a statement confirming regulatory approval had been granted for the use of the drug in South Africa, USA, Australia, Zimbabwe and Malawi for at-risk adults and adolescents weighing at least 35kg to reduce the risk of sexually acquired HIV-1 infection.
WHO advises that individuals must have a negative HIV-1 test prior to being injected with long-acting CAB-LA.
Do you have a story or an opinion to share? Email us on: [email protected] Or join the Daily Express WhatsApp channel for all the latest news and trends or join the Telegram Channel for the latest updates.
